Results 201 to 210 of about 12,004,584 (291)

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study. [PDF]

Front Oncol
Pantano F, Malgeri A, De Giorgi U, Maruzzo M, Fornarini G, Zucali P, Fratino L, Milella M, Pedrazzoli P, Procopio G, Stellato M, Naglieri E, Soto Parra H, Napoli MD, Mollica V, Tudini M, Pipitone S, Santoni M, Ricotta R, Banna GL, Catalano F, Cavo A, Vignani F, Masini C, Casadei C, Galli L, Nolè F, Sorarù M, Prati V, Panni S, Roviello G, Prati G, Morelli F, Messina C, Atzori F, Rescigno P, Santini D, Buti S, Rebuzzi SE.   +38 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Phenotyping cardiogenic shock: an insight from the gulf cardiogenic shock registry. [PDF]

Front Artif Intell
Elmahrouk A, Daoulah A, Jamjoom A, Yousif N, Almahmeed W, Panduranga P, Arabi A, Kanbr O, Aloui HM, Alshehri M, Alzahrani B, Seraj S, Hussien A, Alharbi W, Qutub MA, Kahin M, Alenezi A, Ghani MA, Hassan T, Rajan R, Al Maashani S, Abohasan A, Balghith M, Dahdouh Z, Alqahtani AM, Abdulhabeeb IAM, Al Jarallah M, Aldossari MA, Anthony H, Ashour MAAA, Chachar TS, Khan H, Shawky AM, Elmahrouk Y, Lotfi A, Arafat A.   +35 more
europepmc   +1 more source

Additional Investigations [PDF]

Deutsches Ärzteblatt international, 2016
openaire   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Case Report: Lorlatinib for the treatment of <i>ALK</i>-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor. [PDF]

Front Oncol
Yaringaño J, Hernando J, García-Álvarez A, Iglesias-Felip C, Zafón C, Vivancos A, Roca-Herrera M, Pérez-Fernández S, Martínez-Badal S, Elguero B, Capdevila J.   +10 more
europepmc   +1 more source